Rheumatoid arthritis

Predictions of rheumatoid arthritis burden in 204 countries and territories by 2044: based on the Global Burden of Disease Study 2021

Clin Exp RheumatolPublished Secondary analysis of the Global Burden of Disease Study 2021

Authors' conclusion

Global prevalence and incidence of RA are projected to rise further.

Study context

Population
Rheumatoid arthritis (RA) in 204 countries and territories, 1990–2021, Global Burden of Disease (GBD) 2021 data204 countries and territories
Primary endpoint
Temporal trends in age-standardised prevalence (ASPR), incidence (ASIR) and DALYs (ASDR) of RA, with projections through 2044
Follow-up
1990–2021; projected to 2044
Methodological details204 countries and territories, estimated annual percentage change (EAPC) and average annual percentage change (AAPC) trend analysis, Joinpoint, AutoRegressive Integrated Moving Average (ARIMA) and Nordpred age-period-cohort projections
  • 204 countries and territories
  • EAPC and AAPC trend analysis
  • Joinpoint
  • ARIMA and Nordpred age-period-cohort projections

Primary result

As reported in the abstract

Global RA trends 1990–2021 (AAPC)

Global age-standardised prevalence (ASPR) AAPC

0.44

Global ASIR AAPC

0.40

Global ASDR AAPC (modest decline)

−0.03

Further findings

Highest country rates in 2021

Ireland highest ASPR
529.08
Ireland highest ASIR
35.08
Mexico highest ASDR
87.45

Sociodemographic index (SDI), sex and age differences

Higher SDI regions bore a greater RA burden overall; lower SDI regions had more rapid increases
Women, particularly aged ≥60 years, had higher rates than men across all metrics

Risk factors for RA disability-adjusted life years (DALYs)

Smoking a vital risk of DALYs across age groups, genders and regions

Projections through 2044 (Nordpred and ARIMA)

Continued rapid growth in prevalence and incidence cases, with more gradual increases in ASPR and ASIR

Original publication

Predictions of rheumatoid arthritis burden in 204 countries and territories by 2044: based on the Global Burden of Disease Study 2021. Clin Exp Rheumatol. Published 12 April 2025. doi:10.55563/clinexprheumatol/7dijpb

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.